NCT07015918

A Study to Understand How the Study Medicine (PF-07976016) is Processed and Eliminated in Healthy Men

A PHASE 1, OPEN-LABEL, 2-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION OF [14C]PF-07976016 AND TO ASSESS THE ABSOLUTE BIOAVAILABILITY AND FRACTION ABSORBED OF PF-07976016 IN HEALTHY MALE PARTICIPANTS USING A [14C]-MICROTRACER APPROACH

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Pfizer · Industry
• Sex: Male
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to learn about how much the study medicine PF-07976016 will be taken up and processed by healthy male participants. The total number of weeks of the study is up to approximately 12 weeks.

Conditions

• Healthy Male Volunteers

Interventions

Type	Name	Description
DRUG	[14C] PF-07976016	\[14C\] PF-07976016 liquid (oral) formulation
DRUG	PF-07976016	PF-07976016 liquid (oral) formulation
DRUG	[14C] PF-07976016	\[14C\] PF-07976016 intravenous (IV) formulation

Timeline

• Start date: 2025-06-04
• Primary completion: 2025-07-16
• Completion: 2025-08-14
• First posted: 2025-06-11
• Last updated: 2025-09-10

Locations

1 site across 1 country: Netherlands

Regulatory

• FDA-regulated drug study